Antibody-based therapy of human leukemia.

Eneida R Nemecek's picture
PDF versionPDF version
TitleAntibody-based therapy of human leukemia.
Publication TypeJournal Article
Year of Publication2002
AuthorsNemecek, ER, Matthews, DC
JournalCurr Opin Hematol
Volume9
Issue4
Pagination316-21
Date Published2002 Jul
ISSN1065-6251
KeywordsAntibodies, Monoclonal, Antigens, CD, Antineoplastic Agents, Clinical Trials as Topic, Humans, Immunotherapy, Leukemia
Abstract

During the past decades, monoclonal antibodies have been used as vehicles to deliver targeted therapy to sites of leukemic involvement. Anti-CD33 antibodies have been used alone-and more effectively, attached to chemotherapy agents or radioisotopes-to treat those with acute myeloid leukemia. Anti-CD45 antibodies have demonstrated an antileukemic effect when used either unconjugated or attached to radioactive iodine. Antibodies reactive with the myeloid antigen CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Antibodies reactive with CD52 and CD20 antigens have been studied for the management of B-cell leukemia. This article reviews the most current clinical trials using monoclonal antibodies in the management of leukemia.

Alternate JournalCurr. Opin. Hematol.
PubMed ID12042706